Postmenopausal Hormone Therapy is Associated with in Situ Breast Cancer Risk

Ni, Xiao-Jian; Xia, Tian-Song; Zhao, Ying-Chun; Ma, Jing-Jing; Zhao, Jie; Liu, Xiao-An; Ding, Qiang; Zha, Xiao-Ming; Wang, Shui

추천

검색

자료유형: 학술저널

저자정보: Ni, Xiao-Jian (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) Xia, Tian-Song (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) Zhao, Ying-Chun (Department of Breast Surgery, the Second People's Hospital affiliated with Wannan Medical College) Ma, Jing-Jing (State Key Laboratory of Reproductive Medicine, Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University) Zhao, Jie (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) Liu, Xiao-An (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) Ding, Qiang (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) Zha, Xiao-Ming (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University) Wang, Shui (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제8호

발행연도: 2012.1

수록면: 3,917 - 3,925 (9page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The relationship between postmenopausal hormone therapy (HT) and invasive breast cancer has been extensively investigated, but that with breast carcinoma in situ (BCIS) has received relatively little attention. The aim of our present study was to review and summarize the evidence provided by longitudinal studies on the association between postmenopausal HT use and BCIS risk. Methods: A comprehensive literature search for articles published up to May 2012 was performed. Prior to performing a meta-analysis, the studies were evaluated for publication bias and heterogeneity. Relative risk (RR) or odds ratio (OR) values were calculated using 14 reports (8 case-control studies and 6 cohort studies), published between 1986 and 2012. Results: There was evidence of an association between ever postmenopausal estrogen use and BCIS based on a random-effects model (RR = 1.25, 95% confidence interval (CI) = 1.01, 1.55). However, we found no strong evidence of an association between ever postmenopausal estrogen combined with progesterone use and BCIS using a randomeffects model (RR = 1.55, 95% CI = 0.95, 2.51). Furthermore, our analysis showed a strong association between "> 5 years duration" of estrogen or estrogen combined with progesterone use and BCIS. Furthermore, current use of any HT is associated with increased risk of BCIS in cohort studies. Additional well-designed large studies are now required to validate this association in different populations.

#Postmenopausal hormone therapy #breast carcinoma in situ

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요